AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
Completed
- Conditions
- Non-small-cell Lung Cancer (NSCLC)
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3111
- Registration Number
- NCT03725475
- Locations
- 🇺🇾
Research Site, Montevideo, Uruguay
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 463
- Registration Number
- NCT03721289
- Locations
- 🇺🇾
Research Site, Montevideo, Uruguay
AZD4635 Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD4635 solid oral formulation - fastedDrug: AZD4635 50 mg nano-suspension (reference)Drug: AZD4635 solid oral formulation - fedDrug: AZD4635 solid oral formulation variant 1 - fastedDrug: AZD4635 solid oral formulation variant 2 - fastedDrug: [14C] AZD4635 IV microtracer - fasted
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03710434
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Placebo
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 407
- Registration Number
- NCT03706690
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: TezepelumabOther: Placebo
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 951
- Registration Number
- NCT03706079
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Phase 3
Active, not recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 730
- Registration Number
- NCT03703297
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10000
- Registration Number
- NCT03694470
- Locations
- 🇷🇺
Research site, Moscow, Russian Federation
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT03693300
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
Phase 2
Completed
- Conditions
- Lung Diseases, ObstructiveImmune System DiseasesLung DiseasesRespiratory Tract DiseasesHypersensitivity, ImmediateHypersensitivityAsthmaBronchial DiseasesRespiratory Hypersensitivity
- Interventions
- Biological: TezepelumabOther: Placebo
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT03688074
- Locations
- 🇬🇧
Research Site, Wythenshawe, United Kingdom
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Phase 3
Active, not recruiting
- Conditions
- Unresectable Locally Advanced Urothelial CancerMetastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1246
- Registration Number
- NCT03682068
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath